Los Angeles Capital Management’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $99.4K | Sell |
507
-40
| -7% | -$7.77K | ﹤0.01% | 1337 |
|
|
2025
Q4 | $96.1K | Buy |
+547
| New | +$99.6K | ﹤0.01% | 1425 |
|
|
2024
Q4 | – | Sell |
-1,442
| Closed | -$224K | – | 1147 |
|
|
2024
Q3 | $224K | Buy |
+1,442
| New | +$215K | ﹤0.01% | 1098 |
|
|
2023
Q2 | – | Sell |
-14,330
| Closed | -$2.03M | – | 1197 |
|
|
2023
Q1 | $2.03M | Sell |
14,330
-43,167
| -75% | -$6.18M | 0.01% | 497 |
|
|
2022
Q4 | $8.99M | Sell |
57,497
-30,460
| -35% | -$4.38M | 0.04% | 290 |
|
|
2022
Q3 | $10.8M | Buy |
87,957
+24,573
| +39% | +$3.24M | 0.06% | 260 |
|
|
2022
Q2 | $8.43M | Sell |
63,384
-142
| -0.2% | -$19.3K | 0.04% | 294 |
|
|
2022
Q1 | $8.69M | Buy |
63,526
+2,219
| +4% | +$309K | 0.03% | 287 |
|
|
2021
Q4 | $10.6M | Sell |
61,307
-1,039
| -2% | -$158K | 0.04% | 269 |
|
|
2021
Q3 | $9.06M | Sell |
62,346
-46,100
| -43% | -$6.75M | 0.04% | 280 |
|
|
2021
Q2 | $14.3M | Sell |
108,446
-96,946
| -47% | -$12.7M | 0.06% | 249 |
|
|
2021
Q1 | $26.4M | Sell |
205,392
-116,704
| -36% | -$14.4M | 0.12% | 178 |
|
|
2020
Q4 | $38.4M | Buy |
322,096
+9,724
| +3% | +$1.19M | 0.16% | 120 |
|
|
2020
Q3 | $35.8M | Buy |
312,372
+34,873
| +13% | +$4.12M | 0.16% | 118 |
|
|
2020
Q2 | $31.6M | Buy |
277,499
+247,354
| +821% | +$26.2M | 0.15% | 144 |
|
|
2020
Q1 | $2.42M | Buy |
30,145
+21,072
| +232% | +$2.18M | 0.02% | 489 |
|
|
2019
Q4 | $969K | Sell |
9,073
-5,510
| -38% | -$575K | ﹤0.01% | 849 |
|
|
2019
Q3 | $1.56M | Sell |
14,583
-12,310
| -46% | -$1.26M | 0.01% | 694 |
|
|
2019
Q2 | $2.74M | Sell |
26,893
-18,810
| -41% | -$1.81M | 0.01% | 572 |
|
|
2019
Q1 | $4.11M | Sell |
45,703
-66,986
| -59% | -$5.8M | 0.02% | 476 |
|
|
2018
Q4 | $9.38M | Buy |
112,689
+704
| +0.6% | +$66K | 0.06% | 271 |
|
|
2018
Q3 | $12.1M | Buy |
111,985
+60,030
| +116% | +$6.58M | 0.06% | 308 |
|
|
2018
Q2 | $5.71M | Buy |
51,955
+8,972
| +21% | +$935K | 0.03% | 459 |
|
|
2018
Q1 | $4.31M | Buy |
42,983
+33,090
| +334% | +$3.39M | 0.02% | 460 |
|
|
2017
Q4 | $974K | Sell |
9,893
-99
| -1% | -$9.38K | 0.01% | 867 |
|
|
2017
Q3 | $936K | Buy |
9,992
+7,490
| +299% | +$795K | 0.01% | 834 |
|
|
2017
Q2 | $278K | Buy |
+2,502
| New | +$265K | ﹤0.01% | 1081 |
|
|
2016
Q4 | – | Sell |
-101,769
| Closed | -$8.61M | – | 1175 |
|
|
2016
Q3 | $8.61M | Buy |
101,769
+62,241
| +157% | +$5.23M | 0.07% | 327 |
|
|
2016
Q2 | $3.22M | Buy |
39,528
+26,616
| +206% | +$2.03M | 0.03% | 463 |
|
|
2016
Q1 | $923K | Buy |
12,912
+970
| +8% | +$65.1K | 0.01% | 652 |
|
|
2015
Q4 | $850K | Sell |
11,942
-255,874
| -96% | -$17.2M | 0.01% | 710 |
|
|
2015
Q3 | $16.5M | Sell |
267,816
-22,900
| -8% | -$1.6M | 0.16% | 181 |
|
|
2015
Q2 | $21.1M | Buy |
290,716
+48,327
| +20% | +$3.57M | 0.2% | 154 |
|
|
2015
Q1 | $18.6M | Buy |
242,389
+62,704
| +35% | +$4.49M | 0.17% | 163 |
|
|
2014
Q4 | $12.1M | Buy |
179,685
+515
| +0.3% | +$32.5K | 0.11% | 209 |
|
|
2014
Q3 | $10.9M | Buy |
179,170
+6,380
| +4% | +$393K | 0.13% | 186 |
|
|
2014
Q2 | $10.1M | Sell |
172,790
-287,736
| -62% | -$16.9M | 0.1% | 246 |
|
|
2014
Q1 | $26.7M | Buy |
460,526
+118,380
| +35% | +$6.34M | 0.29% | 100 |
|
|
2013
Q4 | $18.3M | Buy |
342,146
+2,010
| +0.6% | +$119K | 0.2% | 150 |
|
|
2013
Q3 | $21M | Buy |
340,136
+291,745
| +603% | +$17.5M | 0.26% | 113 |
|
|
2013
Q2 | $2.93M | Buy |
+48,391
| New | +$2.88M | 0.04% | 389 |
|
Other funds holding DGX
VCM
VPM
EIG
Los Angeles Capital Management's DGX Position: Q1 2026 in Review
Los Angeles Capital Management reduced its Quest Diagnostics (DGX) stake by 7.3% in Q1 2026, selling an estimated $7.77K and leaving 507 shares worth $99.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1337.
Los Angeles Capital Management first reported a position in DGX in Q2 2013 and has held it in 41 quarters since. The position peaked at $38.4M in Q4 2020. 1,064 funds tracked by Wall St. Rank hold DGX as of Q1 2026.
- Los Angeles Capital Management held 507 shares of Quest Diagnostics worth $99.4K as of Q1 2026.
- Los Angeles Capital Management sold 40 Quest Diagnostics shares in Q1 2026, an estimated $7.77K.
- Quest Diagnostics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #1337 holding.
- Los Angeles Capital Management first reported a position in Quest Diagnostics in Q2 2013 and has held it in 41 quarters since.
- Los Angeles Capital Management's Quest Diagnostics position peaked at $38.4M in Q4 2020.
- 1,064 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.
Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.